|
1
|
Zdenek A, Krejčí M and Vorlíček J: Special
Oncology. 1st edition. Galen, Prague: pp. 382010
|
|
2
|
Thomas R and Wolf J: Personalized therapy
of lung cancer. Onkologie. 35 Suppl 1:S14–S19. 2012. View Article : Google Scholar
|
|
3
|
Li C, Hao L, Li Y, Wang S, Chen H, Zhang
L, Ke B, Yin Y, Suo H, Sun B, et al: Prognostic value analysis of
mutational and clinicopathological factors in non-small cell lung
cancer. PLoS One. 9:e1072762014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dundr P, Hornychová H, Matěj R, Ryška A,
Staněk L and Tichý T: Guidelines for histological examination of
lung carcinoma. Society of Czech Pathologists ČLS JEP. 12–14.
2013.(In Czech).
|
|
5
|
Li Y and Song L: Research progress on
resistance mechanisms of epidermal growth factor receptor tyrosine
kinase inhibitors in non-small cell lung cancer. Zhongguo Fei Ai Za
Zhi. 15:106–111. 2012.(In Chinese). PubMed/NCBI
|
|
6
|
Iqbal N and Iqbal N: Human epidermal
growth factor receptor 2 (HER2) in cancers: Overexpression and
therapeutic implications. Mol Biol Int. 2014:8527482014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ricciardi GR, Russo A, Franchina T,
Ferraro G, Zanghì M, Picone A, Scimone A and Adamo V: NSCLC and
HER2: Between lights and shadows. J Thorac Oncol. 9:1750–1762.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Edge SB, Bryd DR, Compton CC, Fritz AG,
Greene FL and Trotti A III: AJCC Cancer Staging Manual. 7th
edition. Springer; New York, NY: 2009
|
|
9
|
Camidge DR, Theodoro M, Maxson DA, Skokan
M, O'Brien T, Lu X, Doebele RC, Barón AE and Varella-Garcia M:
Correlations between the percentage of tumor cells showing an
anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal
copy number and response to crizotinib therapy in ALK fluorescence
in situ hybridization-positive non small cell lung cancer. Cancer.
118:4486–4494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–47.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Compérat E, Zhang F, Perrotin C, Molina T,
Magdeleinat P, Marmey B, Régnard JF, Audouin J and Camilleri-Broët
S: Variable sensitivity and specificity of TTF-1 antibodies in lung
metastatic adenocarcinoma of colorectal origin. Mod Pathol.
18:1371–1376. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Su YC, Hsu YC and Chai CY: Role of TTF-1,
CK20 and CK7 immunohistochemistry for diagnosis of primary and
secondary lung adenocarcinoma. Kaohsiung J Med Sci. 22:14–19. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yatabe Y, Mitsudomi T and Takahashi T:
TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol.
26:767–773. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bunn PA Jr, Helfrich B, Soriano AF,
Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C and Chan
DC: Expression of Her-2/neu in human lung cancer cell lines by
immunohistochemistry and fluorescence in situ hybridization and its
relationship to in vitro cytotoxicity by trastuzumab and
chemotherapeutic agents. Clin Cancer Res. 7:3239–3250.
2001.PubMed/NCBI
|
|
15
|
Roberts PJ, Stinchcombe TE, Der CJ and
Socinski MA: Personalized medicine in non-small-cell lung cancer:
Is KRAS a useful marker in selecting patients for epidermal growth
factor receptor-targeted therapy? J Clin Oncol. 28:4769–4777. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Riely GJ, Marks J and Pao W: KRAS
mutations in non-small cell lung cancer. Proc Am Thorac Soc. 6:pp.
201–205. 2009, View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pratilas CA, Hanrahan AJ, Halilovic E,
Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A,
Janakiraman M, et al: Genetic predictors of MEK dependence in
non-small cell lung cancer. Cancer Res. 68:9375–9383. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marchetti A, Felicioni L, Malatesta S,
Sciarrotta Grazia M, Guetti L, Chella A, Viola P, Pullara C,
Mucilli F and Buttitta F: Clinical features and outcome of patients
with non-small-cell lung cancer harboring BRAF mutations. J Clin
Oncol. 29:3574–3579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Villaruz LC, Socinski MA, Abberbock S,
Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M,
Franklin WA, Camidge DR, et al: Clinicopathologic features and
outcomes of patients with lung adenocarcinomas harboring BRAF
mutations in the lung cancer mutation consortium. Cancer.
121:448–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schmid K, Oehl N, Wrba F, Pirker R, Pirker
C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung
adenocarcinomas and corresponding locoregional lymph node
metastases. Clin Cancer Res. 15:4554–4560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Katayama R, Shaw AT, Khan TM,
Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT,
Benes C, et al: Mechanisms of acquired crizotinib resistance in
ALK-rearranged lung cancers. Sci Transl Med. 4:120ra172012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
